Top Story

Resveratrol reduces testosterone, DHEAS levels in women with PCOS

Resveratrol reduces testosterone, DHEAS levels in women with PCOS
October 24, 2016

Women with polycystic ovary syndrome assigned the polyphenol resveratrol for 3 months saw a marked reduction in testosterone and dehydroepiandrosterone sulfate vs. those assigned a placebo, according to findings from a randomized trial.

“Our study is the first clinical trial to find resveratrol significantly lowers PCOS patients’ levels of testosterone as well as dehydroepiandrosterone sulfate (DHEAS), another hormone that the body can convert into testosterone,” Antoni J. Duleba, MD, professor and director of the division of reproductive endocrinology and infertility at the University of California, San Diego School of Medicine, said in a press release. “This nutritional supplement can help moderate the hormone imbalance that is one of the central features of PCOS.”

In the Journals Plus

Low-dose aspirin fails to affect menstrual cycles

October 24, 2016
The risk for anovulation is not significantly increased by low-dose aspirin in women with a history of one or two pregnancy losses, study data show. Enrique F

Sanofi and Verily launch diabetes management platform

October 23, 2016
In a joint venture, Sanofi and Verily are launching a diabetes management platform that will provide tools and technology to aid in improving daily life for patients…

Antibody vaccine for treatment of type 1 diabetes enters preclinical trial

October 22, 2016
Neovac, a French company specializing in immunotherapies, will begin studying its interferon-alpha kinoid vaccine for the treatment of type 1 diabetes in collaboration…

Top 5 online thyroid stories posted in the last month

October 21, 2016
Endocrine Today has compiled a list of the top five news reports on the thyroid posted from Sept. 20 to Oct. 20. Healio.com/Endocrinology readers were interested in…
More News Headlines »

Practical Lipidology®: Volume 3, Number 1

This activity is supported by an educational grant from Amgen

The reduction of low-density lipoprotein-cholesterol (LDL-C) is recognized as the primary strategy for decreasing…
More »
Meeting News Coverage

VIDEO: Thyroid imaging approaches not ‘one-size fits all’

September 23, 2016
More »
Cardiometabolic Health Congress

Cardiometabolic Health Congress


The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars…
More »
Current Issues
View the Current Issues